Cancer of the uterine cervix and human papillomavirus infection by Das, B. C. et al.
REVIEW ARTICLE
CURRENT SCIENCE, VOL. 78, NO. 1, 10 JANUARY 200052
Cancer of the uterine cervix and human
papillomavirus infection
B. C. Das*, V. Gopalkrishna, Suresh Hedau and Sanjay Katiyar
Division of Molecular Oncology, Institute of Cytology and Preventive Oncology (ICMR), Maulana Azad Medical College Campus,
Bahadur Shah Zafar Marg, New Delhi 110 002, India
Human papillomaviruses (HPVs) have emerged as the
principal sexually transmitted causal agents in the
development of cancer of the uterine cervix in women. They
also cause a variety of benign lesions, warts, intraepithelial
neoplasia and anogenital, oral and pharyngeal papillomas.
Presently, more than 100 HPV genotypes have been
identified in humans, and about one-third of them have been
sequenced. Of these, while HPV types 16 and 18 are
considered to be the high-risk types, HPV 6 and 11 are the
low-risk types in the development of cervical cancer.
Evidence for causal role of HPV in the development of
cervical neoplasia comes from the etiological and epidemio-
logical observations together with the experimental findings
of the molecular pathways elicited by HPV-transforming
genes. Further evidence in favour of papillomavirus as the
carcinoma virus comes from the findings of presence of HPV
infections in cancers of oral, esophageal, larynx and non-
melanoma skin cancers. The oncogenic potentials of the
virus have been attributed to its E6 and E7 genes. The
products of these two genes stimulate cell proliferation by
activating the cell-cycle-specific proteins and interfere with
the functions of cellular growth-regulatory proteins, p53 and
Rb. Identification and characterization of several human
pathogenic HPV types warrant prevention of viral infection
through vaccination or therapeutic intervention which could
eventually control infection and expression of human
pathogenic papillomaviruses.
CANCER of the uterine cervix is the second-most common
malignant tumour in the world, but is the number one cancer
in Indian women, posing a major public health problem. In
India, about 100,000 women develop this cancer every
year1,2, constituting about 16% of the world’s annual
incidence3,4. It has been estimated that about 1,40,000
women might develop cervical cancer by the turn of this
century5. For over a century, it was believed that cervical
cancer is associated with ‘sexual behaviour’, indicating
involvement of a sexually transmissible infectious agent.
Initially, herpes simplex viruses type 2 (HSV-2) was
considered as the possible candidate, but the absence of
HSV-2 DNA in most cervical tumours together with the
results of several epidemiological studies amply
demonstrated that HSV-2 was not directly involved in
cervical cancer development. It was only in the early 1980s
that the prevailing controversy over the involvement of
human papillomaviruses (HPVs) was settled following
cloning of several HPV genomes, including the most
prevalent HPV-16 from cervical carcinomas and genital
warts6–9. However, it took more than a decade before the
causal role of specific types of HPVs in cancer of the cervix
and their precursor lesions was accepted10,11. Although
papillomavirus particles were first observed by electron
microscopy in human warts in 1949 (ref. 12), their
carcinogenic potential was first demonstrated in shope
papillomavirus13 (later named as cottontail rabbit
papillomavirus (CRPV). Ito and Evans14 successfully
induced carcinoma in domestic rabbits with CRPV DNA
extracted from carcinomas. In 1963, the structure of the
papillomavirus genome was analysed15. Thus it was
established that infection of specific types of HPV was
indeed essential for the development of cervical cancer.
However, to result in malignancy, the probable16,17
involvement of other risk factors and/or cellular events, in
addition to viral infection, was considered a requirement.
  Epidemiological studies did demonstrate the association
of several risk factors with the development of cervical
cancer. The risk factors include sexual promiscuity and
multiplicity of sexual partners18, exposure to sexual
intercourse at an early age19,20, number of pregnancies21,22,
cigarette smoking23,24, use of oral contraceptives25, dietary
and other factors26–28. In addition to these epidemiological
risk factors, the interaction between the genes encoded by
the papillomaviruses and the host cell genes appears to
play a crucial role during tumorigenic progression, including
cellular transformation and interference with the cellular
growth-regulatory tumour suppre sor genes, p53 and Rb.
Since there is an active involvement of HPVs in these
mechanisms, an understanding of immunology of HPV
together with the mechanisms of HPV-induced-
carcinogenesis for developing vaccines against HPVs has
assumed significance.
  In this review we present a brief account of the present
understanding of HPV infections, emphasizing cancer of the
human uterine cervix in India where preval nc  of both HPV
and cervical cancer is reportedly the highest in the world.
Uterine cervical cancer
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The cancers that develop from uterine cervix are of two
types: (i) squamous cell carcinomas, which develop from
squamous epithelium, cover mostly visible part of cervix;
and (ii) adenocarcinomas, which arise from glandular lining
of endocervical canal. About 85% to 90% of cervical
cancers are squamous cell carcinomas, and the rest 10–15%
are adenocarcinomas. Over 90% of these cancers are
diagnosed at advanced stages IIB, IIIB and IV, the majority
of which are presented at 35–64 years
of age29. Squamous cell carcinoma (SCC) is preceded
by well-recognized epithelial changes, the precancerous
lesions, which develop through several grades: cervical
intraepithelial neoplasia (CIN) I to III; or low grade
squamous intraepithelial lesions (LSIL) to high grade
SIL or a mild, moderate and severe dysplasia leading to
carcinoma-in situ (CIS). These lesions may progress to
malignancy, or persist, or regress to normalcy. The distinct
premalignant or dyspla tic changes are generally being
detected by a simple exfoliated cytological screening, th
‘Pap-test’30. The uniquen ss of cervical cancer is that the
precancerous lesions may take a few months to several
years (10–15 years) to progress to the stage of invasive
cervical cancer. Therefore, early diagnosis of premalignant
cervical lesions plays a pivotal role in controlling cervical
cancer.
HPVs: Natural history and transmission
The natural history of HPV infections is not well under-
stood. These viruses normally infect their natural host,
humans, resulting in genital warts or condylomas in the
external and internal genitalia. The infected epithelial cells
show koilocytes, which are indicative of HPV infections.
Koss31 reported that 50–70% of condylomatous lesions of
the cervix are associated with the spectrum of CIN. These
infections may not necessarily lead to visible lesions and
may naturally abort or clear up within a short time. It is the
high-risk HPVs which are considered to be a major risk for
progression of dysplasia to invasive cancer. The relative
risk for women with HPV 16/18 developing CIN is 11
(attributable risk 52%) compared to women without HPV
infection32. HPV infections occur almost exclusively in rare
hereditary disease, the epidermodysplasia verruciformis
(EV). However, the issue of the clonality of intraepithelial
lesions and warts is very much controversial33,34. A clonal
growth of HPV-infected cells showed a requirement for a
highly specific intracellular environment for the
development of lesions, possibly provided by cells that had
undergone specific genetic alterations, since presence of
HPV DNA has been demonstrated in clinically symptom-
free epidermal and mucosal sites of the cervix, larynx and
skin35–38. The persistence of HPV infection is found to be
significantly higher among women infected with high-risk
HPV types (16/18) and perhaps it is this subset of women
that subsequently develop cancer. However, the mode of
viral DNA persistence in such latent infections is still
unkn wn.
  Transmission of HPVs, causing papillomas, is facilitated
by the presence of abraded or macerated epithelial
surfaces39. Anogenital infections are mainly transmitted by
sexual contact, since HPV DNA is rarely detected in
sexu lly inexperienced young women40–43. Occasionally, it is
perinatally transmitted to infants during delivery44,45.
Mo eover, there exists a good correlation between multiple
sexual partners and the prevalence of HPV infection46–49.
O casionally, anogenital HPVs are also transmitted digitally
from one epithelial site to the others50,51. O o-genital contact
m y lead to infections at oral sites by anogenital HPVs52.
Skin infections by HPVs originate from contacts with
co taminated materials, walking barefoot on an abrasive
surface53, or by acquiring accidental epithelial wounding
with contaminated equipment54.
HPVs: Epidemiology
A number of epidemiological risk factors for cervical cancer,
including both biological as well as behaviourable variables,
showing a good correlation between natural history of HPV
infection and cervical cancer have been established. The
current epidemiological data strongly support that HPV
infection is the primary risk factor playing a central role for
development of benign or invasive cervical cancer. HPV
infections and their associated lesions are most prevalent
mong young sexually active women; much less or nil in
nu s or virgins. These infections may resolve
spontaneously within a month or a year, or may persist and
pr gress to high-grade lesions. The additional risk factors
for progression include reproductive factors, cellular
immunity, nutritional factors, socio-economic status, co-
infection by other sexually transmitted infectious agents
such as HSV-2, T. vaginalis, C. trachomatis, etc. The past
or present infections with these pathogens may reflect
s xual promiscuity and act as surrogate markers of exposure
to HPV. Certain cultural/social customs or religion and
personal hygiene may influence HPV infection. Jews and
Muslim women show extremely low prevalenc  of HPV and
cervical cancer. Exposure to sexual intercourse at an early
age and to a large number of sexual partners increase the
chances of HPV infection. Several epidemiological studies55–
58, world- over, have concluded that infection of HPV, parti-
cularly of high-risk HPV types 16 and 18, is the primary risk
factor for cervical cancer after adjusting for all other
co founding variables including smoking, oral contracep-
tives, age at first sexual intercourse and life-time number of
sexu l partners.
  Most interestingly, in India, the association of the
infection of high-risk HPVs with the age of marriage below
18 years has been found to increase the risk of cervical
canc r by 22 fold20. Integration of viral DNA
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too is associated with the progression to malignancy.
Smoking, as a risk factor, though varies from region to
region, may cause genetic damage or suppression of
immune response, leading thereby to progression of HPV
lesions59. Multiple pregnancies and the use of oral contra-
ceptives may enhance HPV infectivity and expression of
HPV-transforming gene.
HPVs: Diagnostic techniques
Diagnosis, particularly of high-risk types of HPVs is
of great importance for presence of clinically latent
papillomavirus infections which are highly prevalent in
general population. Carriers of high-risk HPVs and those
carrying infection show a high rate of progression. However
conventional diagnostic techniques, generally being used,
rely on cytological and histological examination and colpo-
scopy and cannot detect the viruses.
  For a majority of viruses, specific antibody–antigen reac-
tion can be assayed in serological tests by enzyme-linked
immunosorbant assay (ELISA) or western blotting. But,
such assays are not possible for HPVs due to lack of good
source of papillomavirus antigens, since natural occurrence
of HPV virions in cervical lesions is extremely
low, and moreover, this virus cannot be grown in vitro.
Recently, expression of the HPV proteins as fusion proteins
in bacteria, resulted in providing large quantiti s of antigens
which can be used to screen human sera for antibodies
against HPV types, but which of the specific viral antigens
acted as the primary targets of antibody response could not
be ascertained. Therefore, diagnosis of HPV is done only by
molecular hybridization methods.
  Several molecular methods, such as Southern blotting,
dot/slot blotting, filter in situ hybridization (FISH), tissue in
situ hybridization (TISH) and, recently, polymerase chain
reaction (PCR) which is the most sensitive of all, are being
employed for detection of HPV. The first two methods
require purification of cellular DNA from cervical biopsies or
scrapes, followed by the detection of viral genome by
hybridization against radio- or nonradioactive-HPV probes.
Of these two methods, Southern blot hybridization60 allows
identification of HPV types by the sizes of the specific
restriction bands; characteristic of each HPV type (Figure
1). Dot blotting on the other hand, differentiates between
the HPV types by stringency of hybridization. In the FISH
technique, scraped cells are directly filtered onto a
membrane, and the viral DNA is then detected by
hybridization. Though this technique is less time-
consuming, allowing analysis of a large number of
specimens at a time, its limitat ons are low sensitivity and
high false positivity. Tissue in-situ hybridization (TISH)
is specifically important for detecting viral genes on tissue
sections, facilitating analysis of a specimen both at morpho-
logical as well as at the molecular level. PCR61 is highly
sensitive and specific compared to all the other techniques
a d can detect even a single molecule of HPV DNA out of a
million cells. PCR is now being used very commonly for
detection of HPVs using various primers, in variety of
biological specimens including cervical, anal62,63, d oral
scrapes64–68; fine needle aspirates69; urine70, semen, etc71. An
unambiguous amplification of HPV DNA sequences can be
achieved after predigestion of genomic DNA with a single-
cut restriction enzyme of HPVs72. Specific degenerating or
consensus primers are employed for PCR detection of
unknown HPV types73,74. Primer sets from the most
conserved regions such as L1, URR or E6/E7 regions of
HPV genome are the common choice for detection of
specific HPV types. However, the drawbacks of PCR
me hods are: (i) contamination or mixing of cell/DNA
sampl s leading to detection of high frequency of HPVs,
and (ii) selection and use of various primers from different
regions of HPV genome may give different results. To keep
such variations to minimum, proper care should be taken
during each collection, transport, storage and extraction of
DNA from biological specimens including all safety
Figure 1.  Southern blot hybridization analysis of HPV-16 DNA
sequences in cervical biopsy specimens. Ten micrograms of cellular
DNA was digested with PstI, electrophoresed in a 1% agarose gel and
hybridized with the 32P-labelled HPV 16 + 18-DNA probe under
stringent conditions (Tm; – 20°C). Out of the 10 specimens (1–10),
seven w re positive (lanes 1, 3, 4, 6, 7, 9 and 10) for HPV 16. The
characteristic PstI cleavage pattern of HPV 16 is shown by arrows
and the fragment sizes are indicated in kilobases. The first two lanes
are positive control markers having 10 and 50 pg of HPV-16 and
HPV-18 DNA, respectively.
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precautions of running a PCR.
HPVs: Diagnosis in cervical cancer-screening
programme
In developed countries, cytological screening of cervical
precancers by Papanicolaou-stained cervical smears (Pap-
test) and ablation of histologically confirmed lesions have
helped to reduce cervical cancer-based mortality consider-
ably. Primary cervical cancer prevention programme based
on cytological screening which detects changes in cellular
morphology, including HPV infections as koilocytes,
however suffers from several technical limitations besides
high cost, low senitivity, inter-screener variations and
diagnostic errors. Vast amount of data accumulated thus far
suggest that HPV is an undisputed principal etiologic agent
for the development of cervical cancer, and progression of
cervical lesions is always associated with persistent
infection of specific types of high-risk HPVs. Therefore, the
question arises whether cervical cancer screening
programme should also incorporate HPV testing to identify
women at high-risk for developing cervical cancer. But HPV-
DNA test cannot fully replace the Pap-test, since not all
HPV infections lead to cervical cancer, and furthermore,
some cancers also arise without HPV infection. Conversely,
high-risk HPVs can also be detected in a substantial number
of women without cytologic evidence of CIN or other
lesions75. Therefore, to achieve a significant improvem nts
in cancer control programme worldwide, use of both these
diagnostic methods is imperative to augment their
sensitivity, specificity and quality-control of the Pap-test.
This would facilitate identification of substantial number of
women whose smears are neither normal nor abnormal or
suspicious but may progress to invasive cancer if they
harbour insidious infection of HPV.
  It was earlier suggested that in India incorporation of
HPV testing in routine screening is not possible because of
the high cost involved, lack of trained man-power, etc.76.
But, now that specific HPVs have been recognized as the
principal causal agent for the development of cervical
cancer, and since there has been an enormous improvement
and simplification in virus detection
techniques, incorporation of HPV testing in control trials,
particularly for confirming suspicious or negative cases, if
not in routine screening programme, using the same
Papanicolaou-stained slides should be considered.
HPVs: Geographical distribution
Globally, distribution pattern of HPV appears to be similar in
different countries: 60 to 65% positivity for HPV 16; 4 to
20% for HPV 18; and a low prevalence of other HPV types.
An interesting population-based cross-sectional study77,
comparing HPV-prevalence rates of cervical cancer between
a high-risk area (Greenland) and a low-risk area (Denmark)
reported 1.5 times higher HPV 16/18 prevalence in Denmark
compared to Greenland. A comparative study on the
prevalence and type-specific distribution of HPVs from
cervical specimens of women undergoing hysterectomy for
benign, non-neoplastic disease , reported positivity for
HPV DNA in 33% of the cases from Pakistan and 46% of the
cases from Japan; while no significant difference was
reported in prevalence of high-risk HPVs in cancer cases
between the two countries. In a case control study, Munoz
et al.79 reported prevalence of HPVs among controls in
California and Spain to be 3.4 vs 4.3%. But when PCR was
used, a higher prevalence of 13.3% in Califor ian women
than 4.6% in Spanish women was observed. A comparative
study on HPV-prevalence rates among all newly diagnosed
cervical cancer cases in Panama (USA) showed a different
pattern than the one previously reported: HPV-DNA test
conducted in the lowest cancer risk area (30.2 per 100,000) in
contrast to the high-risk areas (51.0 per 100,000), led to the
detection of HPV DNA in 70% of all cases in the former as
opposed to 54% in the latter.
  Reeves et al.80 carried out a large case-control study in
four Latin American countries using FISH and reported that
91% of invasive cancer patients were HPV positive
compared to 63% in controls. This high HPV positivity of
controls however indicates unreliability of the FISH
technique. Lehtinen et al.81 in a nested case-control study
of CIS and ICC from a cohort of 18,814 Finnish women who
were being followed up to a period of 23 years, after the
initial screening, showed that the only significant
association of cervical carcinoma was with the presence of
antibodies to human papillomavirus type 16. (OR: 12.5, 95%
CI: 2.7–5.7). The study revealed that 76% of the CIN lesions
could be attributed to HPV infection, particularly with
oncogenic HPV types.
HPVs, and cervical cancer in India
Studies on cervical cancer in India show (i) as high as 98%
HPV positivity in invasive cancer cases vs 20%
in normal healthy controls; (ii) HPV 16 as the predominant
(90%) type while the frequency of HPV type 18, is very low
(3%) (ref. 82); (iii) HPV 16 is also more frequent than HPV 18
in cervical adenocarcinomas83, but HPV 18 is the
predominant type in other parts of the world84,85; and (iv)
HPV infections are at least two-times more frequent in
pregnant women than in non-pregnant women21,86, showing
a gradual but statistically significant (P < 0.001) increase in
HPV infection with the increasing number of pregnancies21.
Perhaps this is why in India early marriages, normally
resulti g in higher number of pregnancies, is a high-risk
factor for cervical cancer due to immature cervix.
  In a retrospective analysis of specimens from a 12-year
follow-up study, a significant association of HPV 16/18 as a
risk factor for developing cervical cancer has been
de onstrated. Sexual intercourse before 18 years of age has
b en found to increase the risk of cervical cancer by 22
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fold20. Detection of HPV in cervical cancer specimens from
different parts of India82,87–90 indicates that HPV 16 is the
most predominant type. Interestingly, a high frequency
(80%) of HPV 16 was observed in Madras, a high-
prevalence area for cervical cancer91. Th  lowest frequency
of HPV (11%) as well as of cervical cancer were ecorded
from Jammu and Kashmir, while a moderate fr quency
ranging from 42% to 66% has been observed in rest of the
country (Das et al. unpublished data). In precancerous
lesions, the prevalence of HPV 16 and 18
is 54.28%, 52.94%, and 27.08% in severe dysplasia and CIS,
moderate dysplasia, and mild dysplasia, respectively. Das e
al. (unpublished results) have observed a gradual increase
in the rate of HPV infection with increase in the severity of
the lesions.
Other types of papillomavirus infection-linked
cancers in humans
HPVs, particularly the high-risk types, have been detected
in other anogenital cancers as well. Several additional
human cancers too have been linked to human papillo-
mavirus infection. The presence of HPVs in tumours of oral
cavity92–98 (Das et al., unpublished data), larynx99,
tonsil99,100, nasal sinus101, and anogenital carcinomas102
including penile103–105 and anal carcinomas62,63,106,107 have
been recorded in 20%–60% cases. Several reports108–111 on
the role of HPV in esophageal cancers have also been
published. Controversial reports have appeared for the pre-
sence of HPV DNA in cancer of breast112,113, bladder114–117
and urethra118–120. HPV has also been detected in cancer of
the gastrointestinal tract (Das et al., unpublished).
Recently, by using consensus primers, a higher percentage
of varying HPV positivity in various kinds of human
cancers was detected in contrast to a low-HPV positivity in
non-melanoma skin cancers121,122. Quite a few HPV types,
such as HPV types 1, 2, 3, 4 and 27, are associated with
common cutaneous warts, plantar warts and flat warts; but
these are all benign lesions, which mostly regress spon-
taneously. Although a number of different HPV types have
been detected in several human cancers other than cancer
of the cervix, their causal role in inducing these cancers,
though suggestive, has not yet been proved. Therefore,
there is a need to keep track of these HPV infections over a
long period because the virus may not remain as a silent
passenger only, but, instead may have a role as a probable
co-factor in the development of these carcinomas. For the
majority of human cancers associated with HPV infection
that are
of epithelial cell origin, and since HPV is also epitheliotropic
in nature, it is quite likely that the virus
may, in part, contribute to tumorigenic transformation/
progression on these sites.
HPVs: Genomic organization and nomenclature
Human papillomavirus particles are about 55 nm in diameter
and contain a double-stranded closed-circular DNA genome
of approximately 7200 bp–8000 bp. The viral DNA is
encapsidated by 72 capsomeres123, plicating as an
episome in the nucleus of host cells. Human
papillomaviruses belong to a large family of DNA tumour
viruses, papovaviridae, and are epitheliotropic in nature.
The viral early genes or open reading frames (ORFs)
E1–E7, and late genes (ORFs, L1 and L2) are separated by
a transcriptional long control region (LCR) or upstream
regul tory region (URR) (see Figure 2). It contains viral
promoters as well as several enhancer elements, which
control viral replication and transcription of E6 andE7
genes, leading to malignant transformation and maintenance
of tumorigenic phenotype124,125. The LCR/URR constitutes
about 10% of the genome, varying between 800 bp and
900 bp. UR  forms a non-protein-coding region (NCR) of
the viral genome, but it contains many cis-acting elements.
Viral g ne expression is generally regulated by several viral
and host-cell transcription factors, which bind to the URR.
These factors include nuclear factor-1 (NF-1), activator
protein-1 (AP-1), octamer- binding factor-1 (Oct-1), proges-
terone receptor, Yin and Yang factor-1 (YY-1), SP-1, KRF-1
and glucoc rticoid receptor, etc.124,126–128.
  To date, more than 100 different HPV types have been
described: 30 of these types are associated with anogenital
cancers, forming either the high-risk types (HPV 16 and HPV
18) that are associated with anogenital invasive tumours
and their precursor lesions8,9 r the low-risk types (HPV 6
and HPV 11) which rarely progress to malignancy, and are
mainly associated with benign growths, such as genital
warts and condylomas7,129. Analysis of viral genome has
revealed that two early genes E6 and E7 of high-risk HPVs
(16/18) are transforming genes which are responsible for
maintenance of tumorigenic phenotype125,130,131. In contrast,
Figure 2.  Genomic organization and gene functions of papilloma-
viruses exemplified by HPV 18.
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in low-risk HPVs these genes are either nontransforming or
very weakly transforming132–134.
In vitro studies indicate that while proteins encoded by E6,
of HPV 16/18, can form a similar inactivating complex with
p53 tumour-suppressor gene product, p53 (refs 135 and
136), E7 protein forms a stable inactivating complex with
retinoblastoma-susceptibility gene (Rb) product, p105. Thus
these oncoproteins of high-risk HPVs abrogate b th
transcriptional activation as well as cancer suppression (or
growth control) properties exhibited by the p53 and Rb
gene. However, the proteins of low-risk HPVs either cannot
complex or weakly complex with p53 and Rb.
  As for the other ORFs, while E1 is the most conserved
among different HPV types and is responsible for the HPV
replication137 as well as for the site-specific DNA binding
activity138, E2 facilitates E1 binding to the replication origin
located proximally to the URR. The E2 ORF codes for at
least three proteins which act as the transcription factors139.
In high-risk HPV types 16/18, E2 binds to URR and acts as
the transcriptional activator. The E2 is mostly deleted or
disrupted in cervical tumours and cell lines derived from
cervical cancers140–142. This seems to facilitate integration of
HPV genome into the host cell genome and leads to
malignant transformation. This is supported by the
observation that mutation in E2 ORF or its binding sites
within the URR leads to an enhanced immortalization
activity of HPV 16 (ref. 143). The ORF coding for E5 pr tein
also shows transforming activity, but mostly in bovine
papillomavirus (BPV) and is frequently deleted in cervical
cancer141. The role of E4 ORF and its product is not yet
clearly understood but possibly has a role in productive
infection of the virus.
  In 1978, because of the observed genetic heterogeneity
of human papillomavirus, for the nomenclature of a HPV
type, a new type was designated and differed by more than
50% from a prototype HPV, when tested by reassociation
kinetics under stringent conditions of hybridizations144.
Later it was decided that a difference in E6, E7 and L1 ORFs
of more than 10% from the prototype HPV be used to define
a new type. But in 1995, at the Annual Papillomavirus
Conference in Quebec, it was decided that difference in only
L1 ORF exceeding 10% from a prototype be used to define a
new HPV type.
HPVs: Physical state in host cell
Generally, for malignant progression, the integration of viral
DNA into the host cell genome is considered an essential
prerequisite142,145–147. Analysis of the physical state of HPV
DNA in cervical cancer biopsies, and cell lines derived from
tumours indeed confirmed this contention i  most
cases9,142,148–153. However, in premalignant lesions, except in
carcinoma-in situ and severe grades of dysplasia, the HPV
DNA always persists as a nonintegrated episomal
molecule142,147,153,154. The integrated form of HPV DNA can
be revealed by presence and/or shifting of the off-sized
light bands along with HPV-specific authentic BamHI- or
PstI-cleavage pattern which suggests integration of head to
tail tandem repeats at more than one site142,147 (F gure 3).
Several studies including ours145 demonstrated that HPV-16
DNA is present in an integrated form in more than 70% of
cervical cancer specimens, but absence of viral integration
in about 30% of cases indicates that viral integration may
not be a sole prerequisite for malignant transformation.
Several studies, however, have indicated that the analysis
of physical
st te of HPV may serve as a prognostic indicator for
the preneoplastic lesions that are likely to progress to
cancers9,147,155,156. Das and his colleagues145 compared
integration of HPV using at least four different molecular
approaches, including a newly developed PCR method, in
more than 122 cervical specimens comprising the entire
spectrum of cervical lesions, starting from cervical dysplasi
to invasive carcinoma including HPV-positive normal
controls. They reported that integration of HPV increases as
a function of severity of the disease142. It has also been
shown that integration of HPV precedes the invasive stage
and usually disrupts or deletes the E1 or E2 ORF142,157–159.
Disruptions in E2 was also reconfirmed by RNA in situ
Figure 3.  Southern blot hybridization of two cancer biopsy DNA,
following combined digestion with no-cut (NC), HindIII; single-cut
(SC) BamHI; and multi-cut (MC), PstI; in addition to lanes of
undigested (UD) DNA. In the episomal form (a), it shows
characteristic BamHI- and PstI-cleavage patterns along with three
forms of high-M DNA in UD and NC, but no indication of additional
off-sized fragments. In the integrated form (b) there is a shift in light
off-sized fragments (thin arrows) in lanes SC and MC along with
authentic PstI fragments (thick arrows), suggesting integration of
head-to-tail tandem repeats as more than one site.
REVIEW ARTICLE
CURRENT SCIENCE, VOL. 78, NO. 1, 10 JANUARY 200058
hybridization by Daniel et al.154. It has been shown that
disruption of E2 and other genomic regulatory elements
leads to dysregulation of E6/E7 transcription, thereby
increasing the immortalization potential of HPV 16 (ref. 160).
It is clear that viral DNA integration and the resultant
dysregulation of oncogenic activity of E6/E7 is not
sufficient for a malignant phenotype. This is strengthened
by the observation that somatic cell hybridization of
carcinoma cells with normal cells resulted in a non-
malignant phenotype despite the presence of the viral DNA
in an integrated state161,162. Also, in a sizeable proportion of
cervical cancer, HPV DNA remains in an episomal form
indicating thereby that other events perhap  contribute to
tumour progression.
HPV-transforming genes, immortalization and
tumour suppressor genes
The early genes E6 and E7 of high-risk HPV types 16/18,
but not of low-risk types can immortalize human foreskin
and cervical keratinocytes163 after in vitro transfection in
tissue culture. In organotropic cultures, these immortalized
cells share growth characteristics with intraepithelial
neoplasias164. Although HPV E6- and E7-immortalized
human cells are initially nontumorigenic in nude mice, long
term in vitro cultivation results in development of malignant
clones165. These observations indicate that HPV infections
can induce malignant growth, provided a sufficient number
of cell generations are allowed for manifestation of
additional spontaneous or virus gene-induced
modifications. In 1984, immortalizing cells with HPVs were
first attempted166. Later, studies showed that HPV-16 E7
gene can cooperate with the ras oncogene in transforming
primary rat kidney cells166–168. It was in 1987 that
immortalization of human cells with HPV 16 (ref. 169) and in
1988 (ref. 170) with HPV 18 was shown to be possible.
Recent reports in both rodent and human cells show that
only the expression of E6 and E7 genes of high-risk HPVs
is essential for immortalization102,170–172. But, experimental
evidence indicates the additional involvement of specific
host cell genes, engaged in the regulation of signalling
pathways173, as essential for immortalization172,174,175.
  For the high-risk HPVs, the E6 oncoprotein binds to the
product of p53, the tumour suppressor gene, while E7
binds to the products of Rb, the retinoblastoma-suscep-
tibility gene176,177. In contrast, low-risk HPVs (6/11) showed
absence of such a binding178. The interaction of high-risk
HPV E6-E7 oncoproteins with cellular Rb and p53 proteins
could act as an important endogenous factor for
progression of premalignant lesions to malignancy.
On the other hand, mutations in p53 are reported to be
detected in HPV-negative cervical carcinomas and cell
lines179,180.
  Almost 50–80% of all human carcinomas overexpress p53
protein due to mutations in p53 gene, coupled with a strong
tendency for selection of the mutant p53, suggesting a
positive role for tumourigenesis, in addition to the loss of
its tumour-suppressor activity. Several investigators have
tried to identify the specific mutation sites of p53 that are
associated with several cancers, including cervical cancer,
but no such specific mutational hotspots have been so far
identified for cervical cancer, instead, both HPV-positive as
well as HPV-negative cervical carcinomas how a very low
frequency of mutation in p53 gene.
HPVs: Transcriptional regulation
As early as in 1977, zur Hausen proposed that certain
cellular factors control the expression of persisting tumour
virus genomes. Based on this it was assumed that normal
proliferating cells regulate transcription of HPV early genes,
but cervical cancer cells may lack this type of control. A
long persistence of HPV infections, and a very slow rate of
progression of the lesions indicate involvement of a well-
orchestrated modulation of viral replication and
transcription. Transcripts at the start site of E6 promoter are
polycistronic in nature, and are reported to include E2 gene.
One of the events that modulate E6/E7 expression is
integration of HPV DNA into the host cell genome. HPV
integration often leads to inactivation/ disruption of E2
ORF thereby relieving E6 and E7 transcriptional repression
by E2 protein. But in a sizeable proportion of cervical
cancer, HPV DNA remains in an episomal form indicating
involvement of other mechanism(s) for tumour progression.
It is now clear that specific cellular protein factors are
known to participate in the transcriptional control of HPV
oncogene expression. The enhancer elements of HPV 16
and other HPV types were found to be activated by a large
number of host cell transcription factors. Most important of
these include activator protein 1 (AP-1), nuclear factor 1
(NF-1), glucocorticoid receptor and progesterone receptor.
The epitheliotropic nature of HPV, its transcriptional specifi-
city for epithelial cells correlates perfectly with the activity
of AP-1 and NF-1 transcriptional factors.
  Absence of E6/E7 transcription in basal cells of mild
dysplastic lesions and its increased expression in high-
grade lesions and carcinomas indicate that the tumourigenic
progression is caused by the breakdown of intracellular
control mechanisms of HPV-transcription in the basal cells
of the cervical epithelium. Certain addit onal factors such as
growth factor, c-Ha-ras proteins can stimulate E6/E7
transcription via AP-1 which binds to URR. AP-1 can also
act as a target for negative regulation of its target genes by
steroid hormones and retinoic acid receptor-b.
  Recently, it has been shown that transcription factor AP-
1, a heterodimer of c-fos and c-jun oncogenes products,
appears to play a central role in transcriptional regulation of
viral oncogene expression, since point mutations of the
corresponding consensus sequences within the upstream
regulatory region (URR) of HPV 16/18 almost completely
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abolish the expression of viral-transformi g genes, E6 and
E7. Constitutive expression of E6 and E7 is mainly
dependent on the availability of a defined set of
transcription factors derived from the infected host cells.
Recent studies have demonstrated that transactivation and
DNA binding activity of AP-1 or other transcription factors
such as NFkB can be modulated not only by post-
translational modification, such as phosphorylation or
dephosphorylation, but also by alteration of the intracellular
redox status. Agents such as antioxidants which can induce
modification in transcription factors through changes in
cellular redox status may interfere with HPV-specific
transcription. Recently, treatment of a synthetic antioxidant
pyrolidine dithiocarbamate (PDTC) has been shown to
result in the selective suppression of human papillomavirus
gene expression n vitro181. Such studies provide a basis for
development of a novel therapeutic approach to effectively
control the expression of human pathogenic HPVs.
HPVs: Immunology and vaccine
The immune system of the body controls viral infections by
neutralizing the virus with antibodies or by killing
the virus-infected cells. These processes utilize either
antigen-dependent cellular immune response or antigen-
independent phagocytosis by macrophages. Clinical and
histopathological observations however, indicate an impor-
tant role of immune system in controlling HPV infection. It is
now clear that papillomaviruses can elicit both humoral as
well as cell-mediated immune responses which can
be controlled by expression of specfic HLA types (HLA
class I and II antigens). An interesting association has been
shown between expression of specific HLA types and
increased rate of cervical carcinoma182. But, persistent
occurrence of HPV infection in immunocompetent hosts
indicates that perhaps no efficient antiviral immune
response is induced, or else the infected cells escape
immune surveillance.
  It is known that HPV proteins have antigenic properties
and immune response is immunodominant and epitope-
specific. Synthetic peptide-based serology has facilitated
characterization of antibody response to individual HPV
epitopes. Recently, several groups have cloned and
expressed HPV ORFs in expression vectors to generate
bacterial fusion proteins in E. coli. But which viral antigens
are the primary targets of the antibody response require
elucidation. Also, no correlation has been established
between the circulating antibodies and regression of HPV-
induced lesions. Detection of antibodies to HPV proteins in
cancers indicates that all antibody responses are protective,
but no titer of antibody to any HPV protein has been
measured after acute infection. A low prevalence of
antibodies to individual proteins of specific HPV type also
excludes the possibility of using serological assays for
diagnostic purposes. In addition, the fusion proteins are
insoluble, and it is difficult to purify them from the
contaminating E. coli proteins. Several investigators have
g nerated polyclonal or monoclonal antibodies to fusion
prot ins in mice and have used these sera to map
immunoreactive regions using segments of an ORF
expre sed in a bacteriophage library.
 The recent attempts to control HPV-induced diseases are
targeted to develop preventive immunotherapies, and HPV
v ccines to prevent infection with high-risk genotypes such
as HPV 16, 18, 33 and 45. At least three vaccin  strategies
are being developed to control HPV-associated
reneoplastic and neoplastic cervical lesions: (i) therapeutic
vaccines targetting transforming proteins E6 and E7, (ii)
vaccines against existing HPV infection and preneoplastic
lesions targeted to early proteins expressed in suprabasal
stem cells, and (iii) prophylactic vaccines to immunize with
virus-like particles (VLPs) to elicit neutralizing antibodies.
The cellular immune system consists
of two classes of T cells: T-helper cells, which help induce a
B cell response and recognize foreign antigens; and
T-killer cells, which can selectively kill virally infected cells
and recognize foreign antigens. Immunization of mice with
syngeneic non-tumorigenic cells transfected with HPV E6
and E7 conferred protection against transplanted HPV-
positive syngeneic tumour cells. This protection is mediated
by T-killer cells. Therefore, HPV E6 and E7 proteins are
considered to be suitable targets for developing therapeutic
vaccines. However, therapeutic vaccines have not been
found too effective because the mechanism of antiviral
immunity is not clear, and the mode of optimal delivery of
t e v ccine is uncertain.
 Serious efforts are being made towards developing
differ nt effective prophylactic vaccine strategies to control
HPV infection but no HPV vaccine has yet been approved
for human trial. The use of L1 or L2 capsid proteins of HPV
as VLP  has been emphasized because of their high level of
expression in non-mammalian cells. Vaccines have also been
prep r d by using fusion proteins, plasmid DNA, vaccinia
virus recombinants and other methods. But VLPs are most
popularly being used as they lack oncogenic DNA, and
produce large quantities, which are able to elicit high titres
of protective antibody response in animals. These
ntibodies neutralize homologous virions in vitro and
protect against experim ntal challenge in animal models.
This justifies the initiation of human trial of HPV VLP-based
vaccines which could, in principle, eliminate HPV infection,
since humans are the only natural host for these viruses,
but the question that has to be resolved is, will vaccination
against a specific HPV type confer protection against other
HPV types? Results so far obtained in animal system
suggest to the contrary. Furthermore, because of
involvement of at least 30 types of HPVs in anogenital
cancers, initial HPV vaccine developm nt efforts should be
focused on high-risk genotypes only. Since HPV 16 is the
t pe most prevalent throughout the world and is almost
exclusively found prevalent in India, the development of
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vaccine against HPV 16 would be of great help in
controlling cervical cancer. Experimental evidence suggest
that systemic immunization would be able to provide
protection against HPV infection. The intranasal (or
intravaginal) administration of VLPs in combination with
non-toxic mutants of the mucosal adjuvant, cholera toxin
(CT) or labile enterotoxin (LT) could result in protective
immunity against mucosotropic HPVs and other established
HPV infections. Alternatively, live vectors can also be used
for both intranasal administration as well as delivery of
therapeutic antigen vaccines. The use of plasmid DNA as a
vaccine appears to be the most promising approach for
induction of Th1 (T-helper cell class I) or for cell-mediated,
and CTL (cytotoxic T lymphocyte) responses which are
beneficial in antiviral immunity. Immunization with the
plasmid expressing the L1 protein of CRPV was found to be
protective upon subsequent challenge with CRPV183. This
demonstrates that DNA vaccines can work as viable
options for induction of viral protection.
  But before implementation of HPV vaccination, there is a
need for pre-evaluation of their safety and optimization of
administration protocols. One of the most important
questions is selection of target population for vaccination.
Since HPV infection is acquired through sexual contact,
vaccination of adolescents before initiation of their sexual
activity seems to be appropriate. Also, both the partners
need to be vaccinated. But it is quite unlikely that these
vaccines will be useful for women who are currently HPV
positive. In India, though there is no group at present
working specifically on HPV vaccines, efforts should be
made to develop prophylactic as well as therapeutic
vaccines which could bring about substantial reduction in
morbidity from this disease. However, in developing coun-
tries like India, early screening programmes using either Pap
or Pap-HPV test and/or visual inspection of cervix184,185
remain to be the best approaches for control of cervical
cancer until a safe and efficient HPV vaccine can be used in
the general population.
Conclusions
Both epidemiologic and experimental data have establish d
a central role of specific types of HPVs in the genesis of
cervical neoplasia and other human cancers. But none of
these virus infections can cause cancer directly. All of them
seem to require involvement of certainhost cell factors
and/or intracellular control mechanism(s). Correlation of
natural history of HPV infection with development of
cervical cancer reveals a general picture that a women can
have HPV infection following initiation of her sexual
intercourse. The viral infection may be either transient or
may cause early cervical lesions which may regress
spontaneously or progress to higher grade lesions. In some
percentage of women, the infection of HPV may persist and
progress to high grade CIN lesions and eventually to
invasive cancer. The questions that remain to be resolved
finally are:
1. Is sexual intercourse the only possible route for trans-
mission of all HPVs?
2. For reliable screening and effective primary prevention
of cervical cancer, should HPV test be incorporated
along with cytologic Pap-test?
3. What is the mechanism of pathogenesis, epidemiology
and clinical course of small proportion of cervical can-
cers that are HPV-negative, and which also show a
worse prognosis?
4. What is the role of HPV in non-cervical human cancers?
5. What is the clinical relevance of HPV positivity detected
by the ultrasensitive PCR methods?
6. Which vaccine strategy should be adopted for maximum
efficacy, and what set of people should be vaccinated?
  The literature survey indicates that for cervical cancers
that arise in absence of HPV infection, an alternative
pathw y, involving specific cellular gene mutations, is
perhaps responsible. Even in HPV-infected lesions
numerous additional genetic changes186–188 including gene
mutations, should occur in host cells to initiate progression.
Furthermore, analysis of chromosomal abnormalities in
invasive cancer cases suggest alterations in several
oncogenes and tumour suppressor genes. The two HPV-
transforming genes E6 and E7 can functionally interfere
with cell cycle control by interacting with presumptive
tumour suppressor gene products such as p53 andRb
leading to deregulation of cell cycle. Also, the chromosomal
instab lity and aneuploidy, which are often observed in
invasive cervical cancer, may serve as biomarkers. Improved
understanding of immune responses to HPV infection offers
an excellent opportunity in controlling HPV infections by
designing appropriate vaccines, or gene therapy strategies.
Since HPV is the central cause of majority of cervical
cancers, HPV vaccination could be considered as the
ultimate approach for primary prevention and elimination of
cervical cancer.
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